Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

News in Brief

Noted

DOI: 10.1158/2159-8290.CD-NB2015-170 Published February 2016
  • Article
  • Info & Metrics
  • PDF
Loading
  • Under an omnibus spending bill approved by the U.S. Congress, the NIH will receive a $2 billion budget increase for fiscal year (FY) 2016, bringing its total budget to $32.084 billion. Similarly, the NCI and FDA will receive budget increases of more than 5% over their FY2015 budgets. All three agencies have experienced flat funding or outright cuts for more than a decade.

  • According to an analysis by the online health and life-sciences publication STAT, 90% of academic and nonprofit institutions and 74% of drug and device makers do not submit clinical trial results to ClinicalTrials.gov within 1 year of a study's completion, as mandated by law. Although fines can be imposed for failure to comply with the law, none have been levied; STAT estimated that the government could have collected $25 billion from drug companies alone over the past 7 years.

  • Steady reductions in smoking, combined with advances in cancer prevention, early detection, and treatment, have resulted in a 23% drop in the cancer death rate since 1991, averting more than 1.7 million cancer deaths through 2012 (CA Cancer J Clin 2016 Jan 7 [Epub ahead of print]). Also, between 2002 and 2012, mortality rates have declined by 1.8% a year in men and 1.4% in women.

  • Three-dimensional structures of faulty proteins and maps of cancer's communication networks have been added to the canSAR database, launched in 2011 by researchers at The Institute of Cancer Research in London, United Kingdom. canSAR was created to help researchers build a detailed picture of how known human molecules behave and design new cancer treatments. It is available at https://cansar.icr.ac.uk.

  • Despite some promising signs, phase III studies of evofosfamide (TH-302) for the treatment of soft-tissue sarcoma and pancreatic cancer did not meet their primary endpoints, prompting Merck KGaA, which had partnered with Threshold Pharmaceuticals, to stop its development.

Notes

For more news on cancer research, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/content/early/by/section.

  • ©2016 American Association for Cancer Research.
PreviousNext
Back to top
Cancer Discovery: 6 (2)
February 2016
Volume 6, Issue 2
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Noted
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Noted
Cancer Discov February 1 2016 (6) (2) 116; DOI: 10.1158/2159-8290.CD-NB2015-170

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Noted
Cancer Discov February 1 2016 (6) (2) 116; DOI: 10.1158/2159-8290.CD-NB2015-170
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Notes
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • ADC Successfully Targets Urothelial Cancer
  • Break Through Cancer Launches with $250M Pledge
  • By The Numbers: Novel Drugs Approved by the FDA, 2011-2020
Show more News in Brief
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement